Beleodaq approved for aggressive non-hodgkin lymphoma

(HealthDay)—Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes).

Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute estimates.

Beleodaq is designed to inhibit immune cells called T-cells from becoming cancerous, the FDA explained Thursday in a news release. The drug is intended for people whose cancer has returned or who didn't respond to a prior therapy, the agency said.

Beleodaq's safety and effectiveness were evaluated in clinical studies involving 129 people with PTCL. All were treated with the newly approved drug, and about 26 percent had their cancer disappear or shrink, the FDA said.

The most common side effects noted were nausea, vomiting, fatigue, fever and low red (anemia).

Beleodaq is marketed by Spectrum Pharmaceuticals, based in Henderson, Nev.

More information: To learn more about this approval, visit the FDA.

add to favorites email to friend print save as pdf

Related Stories

Imbruvica approved for mantle cell lymphoma

Nov 13, 2013

(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.

Sivextro approved for adult skin infections

Jun 23, 2014

(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.

Cyramza approved for stomach cancer

Apr 22, 2014

(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).

New drug treatment for form of lethal cancer is approved

Jul 06, 2013

A new drug has been approved to battle mantle cell lymphoma, an aggressive cancer often fatal because of its resistance to treatment, after a study led by a Hackensack University Medical Center physician showed it can stop ...

Nexavar approval expanded for common thyroid cancer

Nov 24, 2013

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid ...

Recommended for you

Lanreotide improves survival with enteropancreatic tumors

15 hours ago

(HealthDay)—Lanreotide significantly improves survival among patients with metastatic enteropancreatic neuroendocrine tumors (grade 1 or 2), according to a study published in the July 17 issue of the New En ...

User comments